| Bioactivity | BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research[1][2]. | ||||||||||||
| Invitro | BAY 41-2272 (10 μM; 15 min) increases cGMP levels by itself and synergizes with the NO donor SNP (100 μΜ) in A7r5 rat aortic smooth muscle cells[1]. | ||||||||||||
| In Vivo | BAY 41-2272 (0.3-3 mg/kg; p.o.; single dose; monitored for 12 h) has inhibitory effect in hypertensive dog[2]. Animal Model: | ||||||||||||
| Name | BAY 41-2272 | ||||||||||||
| CAS | 256376-24-6 | ||||||||||||
| Formula | C20H17FN6 | ||||||||||||
| Molar Mass | 360.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Makrynitsa GI, et al. Mapping of the sGC Stimulator BAY 41-2272 Binding Site on H-NOX Domain and Its Regulation by the Redox State of the Heme. Front Cell Dev Biol. 2022 Jun 17;10:925457. [2]. Vogel J, et al. sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension. Hypertens Res. 2021 Dec;44(12):1568-1577. |
BAY 41-2272
CAS: 256376-24-6 F: C20H17FN6 W: 360.39
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.